Loading...
RIV Capital Inc.
RIV.CN•CNQ
Healthcare
Drug Manufacturers - Specialty & Generic
CA$0.10
CA$-0.00(-4.76%)

Over the last four quarters, RIV Capital Inc.'s revenue moved from $1.79M in Q1 2023 to $2.14M in Q4 2023. Operating income in Q4 2023 was -$5.59M, with a strong operating margin of -261%. Despite fluctuations in R&D and SG&A expenses, EBITDA for RIV Capital Inc. remained robust at -$4.33M, reflecting operational efficiency. Net income rose to -$4.99M, with an EPS of -$0.04. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan